All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
DelveInsight’s “Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), historical and forecasted epidemiology as well as Immune Complex Membranoproliferative Glomerulonephritis therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover the Immune Complex Membranoproliferative Glomerulonephritis New Treatment @ https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market
Key Takeaways from the Immune Complex Membranoproliferative Glomerulonephritis Market Report
* On February 02, 2026- Novartis Pharmaceuticals initiated a Phase III study is to evaluate the efficacy and safety of iptacopan compared to placebo (both administered in combination with standard of care) in participants (adults and adolescents aged 12-17 years) with idiopathic IC-MPGN. The study aims to demonstrate a reduction in proteinuria and improvement in estimated glomerular filtration rate (eGFR) in participants treated with iptacopan compared to placebo.
* In January 2026, Apellis Pharmaceuticals Inc. announced a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.
* The total diagnosed prevalent population of IC-MPGN in the 7MM was found to be approximately 7,000 in 2023.
* The diagnosed prevalent population of IC-MPGN, in the United States, was found to be approximately 3,770 in 2023.
* In EU4 and the UK, the diagnosed prevalent population of IC-MPGN was found to be the maximum in Germany, followed by Spain in 2023. While the lowest number of cases were found in Italy.
* In Japan, adults are more prevalent towards IC-MPGN compared to the pediatric group.
* The Immune Complex Membranoproliferative Glomerulonephritis Companies such as Novartis Pharmaceuticals, Apellis Pharmaceuticals, and others.
* Promising Immune Complex Membranoproliferative Glomerulonephritis Therapies such as LNP023, Pegcetacoplan, Danicopan, SGB-9768, Iptacopan and others.
To know more about Immune Complex Membranoproliferative Glomerulonephritis treatment options, visit @ Approved Immune Complex Membranoproliferative Glomerulonephritis Drugs
Immune Complex Membranoproliferative Glomerulonephritis Overview
Membranoproliferative glomerulonephritis (MPGN) is a kidney disorder involving inflammation and kidney cell changes. It is a form of glomerulonephritis caused by an abnormal immune response. MPGN has previously been used as an umbrella term to describe a spectrum of hypocomplementemic glomerular diseases, which are a rare cause of end-stage kidney disease (ESKD). More recently, MPGN has been reclassified into two diseases: immune-complex MPGN (IC-MPGN) and C3 glomerulopathy (C3G) based on immunofluorescence findings in kidney biopsies: predominant or exclusive C3 deposits in C3G and combined immunoglobulins and complement deposits in IC-MPGN.
Immune Complex Membranoproliferative Glomerulonephritis Epidemiology Segmentation in the 7MM
* Total Immune Complex Membranoproliferative Glomerulonephritis Incident Cases
* Total Immune Complex Membranoproliferative Glomerulonephritis Gender-specific Cases
* Total Immune Complex Membranoproliferative Glomerulonephritis Region-specific Cases
* Total Immune Complex Membranoproliferative Glomerulonephritis Treated Cases
Discover more about therapy for Immune Complex Membranoproliferative Glomerulonephritis @ Immune Complex Membranoproliferative Glomerulonephritis Clinical Trials
Immune Complex Membranoproliferative Glomerulonephritis Emerging Drugs
* Iptacopan (LNP023): Novartis Pharmaceuticals
Iptacopan is an investigational, first-in-class, orally administered factor B inhibitor of the alternative complement pathway, targeting one of the key drivers of CDRDs8-10. It is the most advanced asset in the Novartis nephrology pipeline and has the potential to become the first targeted therapy to delay progression to dialysis in C3G9. Discovered at the Novartis Institutes for BioMedical Research, iptacopan is currently in development for several CDRDs where significant unmet needs exist, including IC-MPGN. Currently, the drug is being investigated in Phase III of the clinical development. Novartis intends to seek regulatory approval for the drug by 2026, with the preliminary findings from the Phase III APPARENT trials expected to be available by the same year.
* Pegcetacoplan (APL-2): Apellis Pharmaceuticals
Apellis’ Pegcetacoplan (APL-2) is an investigational, targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. It is a15-amino acid cyclic peptide conjugated to each end of a linear polyethylene glycol molecule that binds to C3 and C3b, directly preventing activation of C3, C5, and the alternative pathway. Pegcetacoplan (marketed as EMPAVELI) is approved in the United States for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Market Outlook
Immune Complex Membranoproliferative Glomerulonephritis Market Outlook
Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) is an ultrarare, chronic, and progressive nephropathy, which is characterized by significant immunoglobulin deposition and is assumed to involve dysregulation of both the classical and alternative pathways of complement (AP). IC-MPGN lacks approved medications, creating a significant demand for treatments addressing the root cause. Kidney failure, necessitating dialysis or transplantation, can occur within 5-10 years of diagnosis. Current strategies involve supportive measures with or without traditional immunosuppression, showing limited effectiveness in slowing disease progression. Considering the diseases’ pathophysiology, a logical approach involves targeted complement inhibition. The utilization of off-label prescription medications predominantly characterizes the market. IC-MPGN treatments encompass immunosuppressants, steroids, inhibitors of renin-angiotensin-aldosterone system (RAAS), and other supportive therapies like calcineurin inhibitors, additional immunosuppressive agents, and antibodies. The current evolving landscape of IC-MPGN treatment exhibits a mid-level pipeline. Two promising therapies, Iptacopan (Novartis Pharmaceutical) and Pegcetacoplan (Apellis Pharmaceuticals), are in the advanced Phase III developmental stage.
Download the report to understand which factors are driving Immune Complex Membranoproliferative Glomerulonephritis therapeutics market trends @ Immune Complex Membranoproliferative Glomerulonephritis Market Trends
Immune Complex Membranoproliferative Glomerulonephritis Companies
Novartis Pharmaceuticals, Apellis Pharmaceuticals, and others.
Scope of the Immune Complex Membranoproliferative Glomerulonephritis Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Immune Complex Membranoproliferative Glomerulonephritis Companies- Novartis Pharmaceuticals, Apellis Pharmaceuticals, and others.
* Immune Complex Membranoproliferative Glomerulonephritis Therapies- LNP023, Pegcetacoplan, Danicopan, SGB-9768, Iptacopan and others.
* Immune Complex Membranoproliferative Glomerulonephritis Therapeutic Assessment: Immune Complex Membranoproliferative Glomerulonephritis current marketed and Immune Complex Membranoproliferative Glomerulonephritis emerging therapies
* Immune Complex Membranoproliferative Glomerulonephritis Market Dynamics: Immune Complex Membranoproliferative Glomerulonephritis market drivers and Immune Complex Membranoproliferative Glomerulonephritis market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
* Immune Complex Membranoproliferative Glomerulonephritis Unmet Needs, KOL’s views, Analyst’s views, Immune Complex Membranoproliferative Glomerulonephritis Market Access and Reimbursement
To learn more about Immune Complex Membranoproliferative Glomerulonephritis Companies working in the treatment market, visit @ Immune Complex Membranoproliferative Glomerulonephritis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of IC-MPGN
4. IC-MPGN Market Overview at a Glance
5. Key Events
6. Epidemiology and Market Forecast Methodology
7. Disease Background and Overview
8. IC-MPGN Treatment
9. Clinical Practice Guideline for the Management of Glomerular Diseases: KDIGO 2021
10. IC-MPGN Epidemiology and Patient Population
11. IC-MPGN Patient Journey
12. IC-MPGN Emerging Therapies
13. IC-MPGN: Seven Major Market Analysis
14. IC-MPGN Unmet Needs
15. SWOT Analysis
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Immune Complex Membranoproliferative Glomerulonephritis Therapeutics Market Size in the 7MM is projected to increase at a significant CAGR by 2034, estimates DelveInsight
